Astellas Pharma Inc (ALPMY)
9.97
+0.27
(+2.78%)
USD |
OTCM |
May 02, 16:00
Astellas Pharma Cash from Financing (Quarterly): -690.16M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -690.16M |
| September 30, 2023 | 3.437B |
| June 30, 2023 | 1.203B |
| March 31, 2023 | -802.38M |
| December 31, 2022 | -56.86M |
| September 30, 2022 | -229.81M |
| June 30, 2022 | -359.65M |
| March 31, 2022 | -684.03M |
| December 31, 2021 | -425.58M |
| September 30, 2021 | -408.45M |
| June 30, 2021 | -408.65M |
| March 31, 2021 | -524.21M |
| December 31, 2020 | -606.53M |
| September 30, 2020 | -355.82M |
| June 30, 2020 | -678.16M |
| March 31, 2020 | 2.818B |
| December 31, 2019 | -723.23M |
| September 30, 2019 | -61.30M |
| June 30, 2019 | -367.16M |
| March 31, 2019 | -570.31M |
| December 31, 2018 | -313.12M |
| September 30, 2018 | -644.14M |
| June 30, 2018 | -580.27M |
| March 31, 2018 | -569.02M |
| December 31, 2017 | -492.81M |
| Date | Value |
|---|---|
| September 30, 2017 | -448.80M |
| June 30, 2017 | -325.40M |
| March 31, 2017 | -434.87M |
| December 31, 2016 | -754.29M |
| September 30, 2016 | -21.02M |
| June 30, 2016 | -326.26M |
| March 31, 2016 | -269.81M |
| December 31, 2015 | -522.03M |
| September 30, 2015 | -357.00M |
| June 30, 2015 | -463.49M |
| March 31, 2015 | -296.77M |
| December 31, 2014 | -218.22M |
| September 30, 2014 | 8.782M |
| June 30, 2014 | -601.37M |
| March 31, 2014 | -4.608M |
| December 31, 2013 | -588.67M |
| September 30, 2013 | -1.381M |
| June 30, 2013 | -297.88M |
| March 31, 2011 | 50.49M |
| December 31, 2010 | -707.59M |
| September 30, 2010 | -532.89M |
| June 30, 2010 | 106.79M |
| March 31, 2010 | 23.57M |
| December 31, 2009 | -633.61M |
| September 30, 2009 | -19.60M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-802.38M
Minimum
Mar 2023
3.437B
Maximum
Sep 2023
3.950M
Average
-408.45M
Median
Sep 2021
Cash from Financing (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | -632.25M |
| Nxera Pharma Co Ltd | 70.34M |
| PeptiDream Inc | 22.30M |
| Stemcell Holdings Inc | 0.00 |
| Healios KK | -10.67M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 340.83M |
| Cash from Investing (Quarterly) | -155.23M |
| Free Cash Flow | 952.05M |
| Free Cash Flow Per Share (Quarterly) | 0.1358 |
| Free Cash Flow to Equity (Quarterly) | 23.46M |
| Free Cash Flow to Firm (Quarterly) | 253.89M |
| Free Cash Flow Yield | 5.28% |